RT info:eu-repo/semantics/article
T1 Dexamethasone PLGA Microspheres for Sub-Tenon Administration: Influence of Sterilization and Tolerance Studies
A1 Barbosa-Alfaro, Deyanira
A1 Andrés-Guerrero, Vanessa
A1 Fernández Bueno, Iván
A1 García-Gutiérrez, María Teresa
A1 Gil-Alegre, Esther
A1 Molina-Martínez, Irene Teresa
A1 Pastor Jimeno, José Carlos
A1 Herrero-Vanrell, Rocío
A1 Bravo-Osuna, Irene
AB Many diseases affecting the posterior segment of the eye require repeated intravitrealinjections with corticosteroids in chronic treatments. The periocular administration is a less invasiveroute attracting considerable attention for long-term therapies. In the present work, dexamethasone-loaded poly(lactic-co-glycolic) acid (PLGA) microspheres (Dx-MS) were prepared using the oil-in-water (O/W) emulsion solvent evaporation technique. MS were characterized in terms of meanparticle size and particle size distribution, external morphology, polymer integrity, drug content,and in vitro release profiles. MS were sterilized by gamma irradiation (25 kGy), and dexamethasonerelease profiles from sterilized and non-sterilized microspheres were compared by means of thesimilarity factor (f2). The mechanism of drug release before and after irradiation exposure of Dx-MS was identified using appropriate mathematical models. Dexamethasone release was sustainedin vitro for 9 weeks. The evaluation of the in vivo tolerance was carried out in rabbit eyes, whichreceived a sub-Tenon injection of 5 mg of sterilized Dx-MS (20–53 µm size containing 165.6 ±3.6 µgDx/mg MS) equivalent to 828 µg of Dx. No detectable increase in intraocular pressure was reported,and clinical and histological analysis of the ocular tissues showed no adverse events up to 6 weeksafter the administration. According to the data presented in this work, the sub-Tenon administrationof Dx-MS could be a promising alternative to successive intravitreal injections for the treatment ofchronic diseases of the back of the eye.
SN 1999-4923
YR 2021
FD 2021
LK https://uvadoc.uva.es/handle/10324/71460
UL https://uvadoc.uva.es/handle/10324/71460
LA eng
NO Pharmaceutics 2021;13:228
NO Producción Científica
DS UVaDOC
RD 27-dic-2024